UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/02/26
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBCGlobeNewsWire • 02/27/26
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026GlobeNewsWire • 02/23/26
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech SummitGlobeNewsWire • 02/04/26
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyGlobeNewsWire • 01/05/26
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/25/25
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains MomentumGlobeNewsWire • 11/06/25
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA TrialGlobeNewsWire • 11/06/25
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewsWire • 11/04/25
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025GlobeNewsWire • 10/30/25
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/25
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026GlobeNewsWire • 10/27/25
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder CancerGlobeNewsWire • 10/02/25